There is a moment in almost every Parkinson's clinic appointment when the questions about dose and timing run out and someone in the room, often the person who drove, asks the real one: is anything coming? Families living with Alzheimer's have had a tidy annual answer for a decade, an audited count of the pipeline they can hold in their hands. For Parkinson's, the answer has usually arrived as whatever press release happened to land that month. Now there is a number to put against it, and it covers ten years.
Writing in the Journal of Parkinson's Disease, published online on 26 May 2026, Susan Buff, Aleksandra Pilcicka, Kenneth Pitzer, Brian Fiske, Simon Stott and Kevin McFarthing counted every Phase 1 to Phase 3 drug trial for Parkinson's registered on ClinicalTrials.gov between 2015 and 2024. The total: 444 trials, testing 281 distinct agents. Forty-two per cent of those trials were Phase 1, 46 per cent Phase 2, and only 12 per cent Phase 3, the large, long, expensive stage where a drug either proves itself or does not. A third of the agents (39 per cent, 109 of 281) were drugs already approved for something else and repurposed; half were genuinely new; the rest were reformulations of medicines people with Parkinson's already take. One hundred and thirty three of the trials were still running at the end of the period, with the authors' data cut-off of 16 January 2025. This is a census of registrations, an extension of the team's five annual snapshot reports, not a trial and not a verdict on any drug in it.
The split inside that total is where the story lives. Two hundred and seventy nine trials, testing 165 agents, were symptomatic: they aimed to make the day better without touching the underlying disease. One hundred and sixty five trials, testing 116 agents, were disease-modifying, aiming to slow or stop progression. Across the whole decade that is 63 per cent symptoms and 37 per cent disease modification, but the balance shifted: between 2022 and 2024, more than half of newly registered Parkinson's drug trials were disease-modifying for the first time. Cure Parkinson's, which co-produced the analysis with the Michael J. Fox Foundation, notes that almost 14 per cent of the disease-modifying work targeted alpha-synuclein, the protein that aggregates in Parkinson's, with the rest spread across inflammation, mitochondria and energy metabolism, the gut microbiome, oxidative stress, and the genetic forms tied to GBA1 and LRRK2. Fourteen of the drugs in the dataset are approved to treat Parkinson's symptoms. None is approved to change the course of the disease.
For readers whose lives have been reshaped less by tremor than by the slow fog that can follow it, the interesting column is the non-motor one, and it is thin. Over ten years, the census counted eight agents tested for cognition or mild cognitive impairment in Parkinson's, four for dementia, four for psychosis and three for hallucinations, alongside eight for constipation, six for depression, five for impulse control disorders and three for anxiety. Set that against the crowded field of levodopa and dopamine agonist reformulations aimed at motor fluctuations and it is a clear, uncomfortable picture: the cognitive and neuropsychiatric end of Parkinson's, the part that most often decides whether someone can stay at home, has attracted a small fraction of the industry's attention. Counting it is not the same as fixing it, but a family who has sensed this for years can now point to a peer-reviewed number instead of a feeling.
The comparison the sceptics will reach for is Alzheimer's, where the tenth annual pipeline report, published in Alzheimer's and Dementia: Translational Research and Clinical Interventions in May 2026, logged 192 active trials assessing 158 drugs as of 1 January 2026. The two counts are not built the same way, one a ten-year retrospective of registrations and the other a single-day snapshot of active studies, so the totals should not be stacked against each other like scores. What is comparable is the habit: a discipline that counts itself in public can see its own gaps, and both counts now show the same structural bottleneck, plenty of early-phase activity and very little reaching the last stage.
What happens next is already scheduled. Cure Parkinson's says results from several advanced trials are expected during 2026, among them the LUMA Phase 2b study of a LRRK2 inhibitor from Biogen and Denali, the Phase 3 ASPro-PD trial of ambroxol, a licensed cough medicine being repurposed, and a Phase 3 study of Roche's anti-alpha-synuclein antibody prasinezumab. None of those readouts is in yet, and a trial appearing in a census says nothing whatever about whether it will work.